Education: B.S. in Biomedical Engineering, Minor in Computer Science, University of Delaware; M.Phil. in Bioscience Enterprise, University of Cambridge

Policy Experience & Interests: Daniel has performed strategic analyses of technical and commercial landscapes for next-generation, early cancer diagnostics within the biotechnology sector, which exposed him to the complex interactions occurring between multiple stakeholders in both the US and UK healthcare systems. Additionally, Daniel has quantitative experience performing health economic modeling of novel oncology diagnostics to understand the cost-effectiveness of these new technologies. This work highlighted to him the effects that policy and regulation have across the many industries that interact together to ultimately affect patient outcomes. He is interested in understanding how novel financing approaches and the utilization of health-economic analyses can address issues pertaining to drug pricing and access on the regional and national level.